NIH Offers Exclusive License for RXFP1 Agonist Inventions
Published Date: 7/23/2026
Notice
Summary
The National Institutes of Health plans to give Modala Bio an exclusive license to use new RXFP1 agonist inventions that could help treat diseases like cancer, heart failure, and fibrosis. This means Modala Bio gets special rights to develop and sell these promising medicines worldwide. If you want to comment or apply for a license, you have until August 24, 2026, so don’t miss out!
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Exclusive RXFP1 License to Modala Bio
The National Institutes of Health is contemplating granting Modala Bio an exclusive patent license to novel RXFP1 agonists, with a prospective territory that may be worldwide and a field of use limited to treatments for cancers, cardiovascular, pulmonary, and fibrotic diseases. This exclusive right would give Modala special commercial control over these inventions.
Prospective License Will Be Royalty-Bearing
The notice states the prospective exclusive license to practice the RXFP1 inventions will be royalty-bearing, meaning the licensee would pay royalties to the patent owners or the government under the license terms. This condition applies if the exclusive license is granted.
Deadline to Apply or Comment
If you want to apply for a license or submit comments about the contemplated exclusive license to Modala Bio, your written materials must be received by the National Center for Advancing Translational Sciences on or before August 24, 2026. License applications will be presumed to contain business confidential information, while general comments and objections (not in license applications) may be made publicly available.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-18191, Submission for OMB Review; 30-Day Comment Request Data and Specimen Hub (DASH) (Eunice Kennedy Shriver National Institute of Child Health and Human Development)
The National Institutes of Health (NIH) is asking for public feedback on their Data and Specimen Hub (DASH), which helps researchers share important health data. This is a quick 30-day review to make sure the information collection is clear and useful. If you’re involved in health research or data sharing, your input by October 8, 2026, can help shape how DASH works without costing extra money or time.
2026-17899, Proposed Collection; 60-Day Comment Request; Assurance (Interinstitutional, Foreign, and Domestic) and Annual Report (Office of the Director)
The NIH wants your thoughts on their plan to keep track of animal research safety through yearly reports and assurances from institutions, both in the U.S. and abroad. This helps make sure labs follow the rules and protect animals, with no new costs or big changes expected. You’ve got until October 2, 2026, to share your feedback and help improve the process!
2026-17687, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in October 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, ensuring fair and confidential decisions. Scientists applying for grants in genetics, molecular sciences, oral health, and cancer research are the ones affected, with no direct cost changes announced.
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
Previous / Next Documents
Previous: 2026-14841, Quarterly Publication of Individuals, Who Have Chosen To Expatriate
Every few months, the IRS shares a list of people who gave up their U.S. citizenship or long-term resident status. This update covers those who lost it by June 30, 2026. If you’re thinking about expatriating, know this process is official, public, and can have tax and timing consequences.
Next: 2026-14855, Intent To Request Extension From OMB of One Current Public Collection of Information: Transportation Security Officer Medical Questionnaire
The TSA is asking to keep using its medical questionnaire for Transportation Security Officer (TSO) candidates to make sure they’re fit for the job. They want to extend this paperwork approval and are inviting the public to share thoughts by September 21, 2026. This won’t cost extra money but helps keep airport security strong and safe!